TTY Biopharm Co (ROCO:4105) ROCE %: 27.65% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4105 TTY Biopharm Co Ltd ROCO:4105
83 GF Score
Price NT$78.10
GF Value NT$87.56
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is TTY Biopharm Co ROCE %?

TTY Biopharm Co ROCO:4105 +0.39% 83 ROCE % is 27.65% as of Mar. 2026. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TTY Biopharm Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.65%.

TTY Biopharm Co  (ROCO:4105) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TTY Biopharm Co ROCE % Related Terms

TTY Biopharm Co ROCE % Historical Data

* Premium members only.

The historical data trend for TTY Biopharm Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTY Biopharm Co ROCE % Chart

TTY Biopharm Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.95 22.15 20.82 25.17 25.90

TTY Biopharm Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.26 21.84 39.42 21.31 27.65
ROCO:4105
83GF Score
TTY Biopharm Co Ltd ROCO:4105
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TTY Biopharm Co ROCE % Calculation

TTY Biopharm Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=2163.834/( ( (10862.766 - 2862.409) + (11348.069 - 2639.833) )/ 2 )
=2163.834/( (8000.357+8708.236)/ 2 )
=2163.834/8354.2965
=25.90 %

TTY Biopharm Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=2317.768/( ( (11348.069 - 2639.833) + (11675.866 - 3621.362) )/ 2 )
=2317.768/( ( 8708.236 + 8054.504 )/ 2 )
=2317.768/8381.37
=27.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.65% mean?
TTY Biopharm Co (ROCO:4105) has a ROCE % of 27.65% as of Mar. 2026.
Is TTY Biopharm Co's ROCE % too high?
TTY Biopharm Co's current ROCE % is 27.65%. The Drug Manufacturers industry median ROCE % is 7.06. TTY Biopharm Co's value of 27.65% is 291.6% above this industry median. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's ROCE % compare to ZTS and UTHR?
TTY Biopharm Co's ROCE % of 27.65% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. TTY Biopharm Co's value of 27.65% is 291.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current ROCE % of 27.65% is 291.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current ROCE % is 27.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$78.10 — trading 10.8% below its estimated fair value. The current ROCE % is 27.65% and 291.6% above the Drug Manufacturers industry median of 7.06. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current ROCE % is 27.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?

Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued. The current stock price of NT$78.10 is trading 10.8% below its estimated GF Value™ of NT$87.56. GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.

Key valuation signals for ROCO:4105:

  • ROCE %: 27.65%
  • GF Value™: NT$87.56 vs. price of NT$78.10 (10.8% below fair value)
  • GF Score™: 83/100 with 1 warning sign
  • Industry Position: 291.6% above the Drug Manufacturers median

No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TTY Biopharm Co Business Description

Address No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score

Get the complete analysis for ROCO:4105

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$78.10
Price
NT$87.56
GF Value